Growth Metrics

Maravai Lifesciences Holdings (MRVI) Operating Expenses (2020 - 2025)

Maravai Lifesciences Holdings has reported Operating Expenses over the past 6 years, most recently at $71.6 million for Q4 2025.

  • Quarterly results put Operating Expenses at $71.6 million for Q4 2025, up 25.48% from a year ago — trailing twelve months through Dec 2025 was $328.0 million (down 22.06% YoY), and the annual figure for FY2025 was $249.3 million, down 27.53%.
  • Operating Expenses for Q4 2025 was $71.6 million at Maravai Lifesciences Holdings, up from $46.7 million in the prior quarter.
  • Over the last five years, Operating Expenses for MRVI hit a ceiling of $197.8 million in Q3 2024 and a floor of -$67.5 million in Q4 2023.
  • Median Operating Expenses over the past 5 years was $75.4 million (2022), compared with a mean of $73.7 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 252.75% in 2021 and later plummeted 170.65% in 2023.
  • Maravai Lifesciences Holdings' Operating Expenses stood at $73.9 million in 2021, then rose by 29.18% to $95.5 million in 2022, then plummeted by 170.65% to -$67.5 million in 2023, then soared by 184.64% to $57.1 million in 2024, then rose by 25.48% to $71.6 million in 2025.
  • The last three reported values for Operating Expenses were $71.6 million (Q4 2025), $46.7 million (Q3 2025), and $113.7 million (Q2 2025) per Business Quant data.